Chronic GvHD (cGvHD) is an important cause of post-transplant morbidity and mortality with an incidence of 40%-60%. 1 Prednisone, alone or with calcineurin inhibitors, is the most commonly used therapy but the response rate is only~50% and most subjects subsequently fail. 2, 3 There is no standard therapy for failures and participation in clinical trials is recommended. Thalidomide is active in mouse models of cGvHD and tested for prevention and therapy of cGvHD in humans. [4] [5] [6] [7] [8] However, doses expected to be effective were poorly tolerated because of somnolence, neuropathy and constipation. Pomalidomide is a new immune-modulating drug with 4000-fold greater inhibition of TNF-α relative to thalidomide. In randomized studies in persons with multiple myeloma, pomalidomide was well-tolerated at doses up to 4 mg/d and without the adverse effects associated with thalidomide.
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Prednisone, alone or with calcineurin inhibitors, is the most commonly used therapy but the response rate is only~50% and most subjects subsequently fail. 2, 3 There is no standard therapy for failures and participation in clinical trials is recommended. Thalidomide is active in mouse models of cGvHD and tested for prevention and therapy of cGvHD in humans. [4] [5] [6] [7] [8] However, doses expected to be effective were poorly tolerated because of somnolence, neuropathy and constipation. Pomalidomide is a new immune-modulating drug with 4000-fold greater inhibition of TNF-α relative to thalidomide. In randomized studies in persons with multiple myeloma, pomalidomide was well-tolerated at doses up to 4 mg/d and without the adverse effects associated with thalidomide. 9 Several features of pomalidomide suggest it may be useful in treating cGvHD. Despite recent advances in understanding the disease processes, 10 the pathogenesis of cGvHD is unknown. Consequently, it is impossible to predict the impact of pomalidomide on cGvHD except in a clinical trial. 11 This was a single institution, open label, pilot study of safety and efficacy of pomalidomide in subjects with corticosteroid-refractory cGvHD (NCT00770757). Approval was obtained from the Institutional Review Board and subjects gave written informed consent. Eligible subjects were ⩾ 18 years old in complete haematologic remission following an allotransplant and with moderate or severe cGvHD. Subjects with overlap cGvHD were allowed on-study, whereas subjects with late-onset acute GvHD were excluded. Subjects must have failed high-dose corticosteroids (0.5 mg/kg/d prednisone for ⩾ 2 months) or second-line immune suppression. Subjects receiving corticosteroids at enrollment had to be on a stable or decreasing dose for ⩾ 2 months and no new immune suppressive drugs were allowed ⩽ 1 month before study entry. Extracorporeal photopheresis, if given, had to be completed ⩾ 3 months before study entry. Karnofsky performance score had to be ⩾ 60%, life-expectancy ⩾ 3 months, platelets ⩾ 75 × 10E+9/L, neutrophils ⩾ 1 × 10E+9/L, creatinine clearance ⩾ 50 mL/min, cardiac ejection fraction ⩾ 40% and no uncontrolled infections.
Pomalidomide was given orally starting at 3 mg/d continuously with dose reductions to 2 mg, 1 mg and 0.5 mg/d for intolerance. Dose-escalation was not allowed. After the first eight subjects were enrolled the study was amended to start pomalidomide at 2 mg/d. Every 28 days of the treatment was considered 1 cycle, 12 of which were planned. Decrease in corticosteroid doses were permitted beginning 6 weeks after enrolment. Two corticosteroid pulses with subsequent rapid taper were allowed while on-study, one at the beginning of study in case of a flare of cGvHD associated with pomalidomide and one later, for flares occurring during the taper of immunosuppression. Subjects received aspirin, 325 mg/d to prevent thromboembolic events. Subjects completing ⩾ 3 cycles of therapy were evaluable for efficacy. cGvHD activity was assessed at baseline, every 3 cycles and when therapy was stopped for any reason, using the NIH Criteria. 12, 13 Complete organ response (CR) was defined as resolution of all reversible cGvHD features in a specific organ, partial organ response (PR) as ⩾ 50% improvement in the specific organ, progression as ⩾ 25% increase on the same scale and stable disease as no change in cGvHD. Complete overall response was defined as complete resolution of all reversible features in all affected organs and partial overall response as an improvement in at least one organ without progression in any other affected organ. Subjects with ⩾ stable disease at the 3-month evaluation were allowed to continue on study. The study would stop accrual if there was no subject with ⩾ PR at the 6-month evaluation. Subjects receiving ⩾ 1 dose of pomalidomide were evaluable for safety. Adverse events were graded according to the NCI Common Toxicity Criteria, Version 3.0. Subjects were followed for adverse effects for 30 days after the last dose of pomalidomide. Descriptive statistics were used for most analyses.
Between February 2009 and June 2010, 13 subjects were enroled (Table 1 ). There were 6 males; median age of all patients was 46 years (range, 27-64 years). Eight of 13 patients received TBR as part of conditioning for transplant. Median Karnofsky performance score was 80% (range, 60-90%). Pomalidomide was started a median of 2.5 years post-transplant (range, 1.8-15 years) and 1.5 years after cGvHD diagnosis (range, 0.5-14 years). Median number of prior therapies was 4 (range, 2-6). Major organ systems involved were skin (N = 13), eyes (N = 10), joint/fascia (N = 10), mouth (N = 9) and lungs (N = 8; Table 1 and Supplementary  Table 1 ). Twelve subjects had severe fibrotic features of cGvHD.
The first eight subjects started pomalidomide at 3 mg/d. Seven required dose-reductions, 4-2 mg/d, 2-1 mg/d and 1-0.5 mg/d ( Table 2 ). The subject without a dose-reduction discontinued from the study after 5 weeks. The next five subjects started at 2 mg/d; two required dose reductions to 1 mg/d. Median therapy duration was 4 cycles (range, 1-12 cycles). Four subjects discontinued therapy after o 3 cycles because of adverse effects with no response and are unevaluable for efficacy analyses. Six subjects received 3-7 cycles and three subjects, 10-12 cycles. We present responses at 3 and 6 months and study end ( Table 2) . Although some symptoms fluctuated, responders after 3 cycles had sustained responses at last evaluation. Three subjects had a PR and 2 subjects a CR of skin erythema; one subject a PR of movable sclerosis; two subjects a CR of mouth cGvHD; three subject a CR and one subject a PR of eye cGvHD and two subjects a CR of GI symptoms (Supplementary Table 2 ). Seven subjects had a partial overall response and two subjects had stable disease. No subject had a complete overall response nor progression. Several subjects had physician-assessed disease worsening not qualifying for progression and were discontinued. No subject with severe skin sclerosis had a measurable response, but several had skin softening not qualifying for a PR. This benefit could be related to the anti-fibrotic properties of pomalidomide.
14 Two subjects received 2 and 5 subjects, 1 corticosteroid pulse. At study end two subjects had a dose reduction of ⩾ 50% in prednisone (40-15 mg/d and 50-17.5 mg/d).
The most common adverse effects and reasons for dose reductions or study-discontinuation were worsening tremors/ shakiness (N = 4), muscle cramps/ musculoskeletal pain (N = 12), neuropathy (grade 3; N = 1; grade ⩽ 2; N = 3) and fatigue/anxiety (N = 6). One subject developed erythematous, cellulitis-like skin rash after several weeks on-study which did not improve after a corticosteroid pulses. She was thought to have an allergic reaction to pomalidomide vs flare of cGvHD and was discontinued after 5 weeks. 15 In addition, in trials of thalidomide for cGvHD, several subjects had initial exacerbation of skin rash. 8 Several subjects Abbreviations: cGvHD = chronic graft-versus-host disease; GI = gastrointestinal; HCT = hematopoietic cell transplant; KPS = Karnofsky performance score; MRD = HLA-matched related donor; MUD = HLA-matched unrelated donor; Rx = therapies. Letter to the Editor complained of low energy, anxiety and depression. Sedation, severe somnolence or severe bone marrow suppression were not observed. Nausea and constipation were rare and mild. Most adverse events improved with dose reductions. No subject relapsed or developed a new cancer. Several subjects developed infections but (pneumonia (N = 3), sepsis (N = 1) and aseptic meningitis (N = 1)); all recovered. Although these events should be considered possibly related to pomalidomide, subjects were severely immune suppressed at baseline with long-standing severe cGvHD, and therefore at risk for infection. One subject receiving aspirin developed a deep vein thrombosis and pulmonary embolism 4 months after starting pomalidomide and was discontinued.
Median follow-up from study-entry is 4.6 years (range, 1.4-5.6 years). Five subjects died, all after stopping pomalidomide ( Table 2) . Four were on-study o 3 cycles and 1 subject intermittently for 5 cycles; all were non-responders. The 7 pomalidomide responders are alive.
Lymphocyte subsets analysis was performed in 7 subjects at predetermined time points. Although we cannot make definitive conclusions based on our few subjects, we noticed alterations in various T-cell subsets during pomalidomide therapy (Supplement).
Our data suggest pomalidomide can be given with an acceptable adverse effects profile to persons with advanced corticosteroid-refractory cGvHD at doses of ⩽ 2 mg/d. However, it is difficult to evaluate efficacy from this small, uncontrolled series. Assessments were made by a transplant subspecialist trained in cGvHD but who was not blinded to therapy assignment. The outcomes we report may therefore reflect biases. Another possible limitation of our study is that most of our subjects had potentially irreversible cGvHD abnormalities such as chronic dry eyes, bronchiolitis obliterans and/or advanced skin sclerosis with joint contractures and have failed many prior therapies. Whether pomalidomide would be more effective in less advance disease should be tested. The study allowed two steroid pulses (up to 1 mg/kg/day) with subsequent rapid taper. It may be argued some responses were a result of this intervention and not pomalidomide. However, these subjects had corticosteroidrefractory disease with a median interval since cGvHD onset of 2 years making a response to corticosteroids pulses unlikely.
In summary, our data suggest modest efficacy when pomalidomide is given for ⩾ 3 months. We recommend future phase-2 studies enter subjects with less advanced disease with reversible abnormalities. A starting dose of 0.5-1 mg/d might be better tolerated and allow longer treatment and possibly, better skin sclerosis responses. Pharmaco-kinetics and -dynamic data should be collected and associations with safety and efficacy tested. Based on our results, a phase-2 study of pomalidomide for cGvHD is ongoing (NCT01688466). Ultimately a randomized, double-blind placebo-controlled trial will be needed to evaluate efficacy.
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